<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362130">
  <stage>Registered</stage>
  <submitdate>21/02/2012</submitdate>
  <approvaldate>8/06/2012</approvaldate>
  <actrnumber>ACTRN12612000622808</actrnumber>
  <trial_identification>
    <studytitle>The Neurocognitive Sub Study of Encore1:A Randomised, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus 2N(t)RTI in Antiretroviral-naive HIV-Infected Individuals Over 96 Weeks</studytitle>
    <scientifictitle>A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naive HIV-infected Individuals Over 96 Weeks</scientifictitle>
    <utrn />
    <trialacronym>The Neurocoginitive sub study of Encore1</trialacronym>
    <secondaryid>NCT01516060 ClinicalTrials.gov</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Tenofovir (TDF) (300mg qd(once daily)/emtricitabine(FTC) (200mg qd) + efavirenz(EFV )(400mg qd; 2 x 200mg + 1 x  placebo qd) all oral tablets

http://clinicaltrials.gov/ct2/show/NCT01516060?term=Encore1&amp;rank=4</interventions>
    <comparator>Tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + efavirenz(EFV )(600mg qd; 3 x 200mg qd) all oral tablets</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is the comparison between neurocognitive function in patients initiating sdEFV and 400EFV

Neurocognitive function will be assessed by using a the CogState Battery, computer software designed to assess neurocognitive function</outcome>
      <timepoint>48 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The association between week 4 plasma EFV levels and change from baseline neurocognitive function to week 4 and 24.</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All subjects entering into the main study protocol at participating centres will be eligible to enter this sub-study</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Existing neurological brain disease
Recent (&lt;6months ) head injury
Current major depression or psychosis
Current alcohol abuse
Intended use of recreational drugs during study period
Uncontrolled medical conditions deemed to potentially interfere with cognitive function (e.g. uncontrolled diabetes, pyrexial illness, uraemia etc)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software (ie computerised sequence generation)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>124</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2010</postcode>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Johannesburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Chennai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Kirby Institute, Univeristy of New South Wales</primarysponsorname>
    <primarysponsoraddress>Gate 9
High Street
Kennsington
Univeristy of New South Wales
Sydney
NSW 2052</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>The HIV Netherlands Australia Thailand Research Collaboration</othercollaboratorname>
      <othercollaboratoraddress>The Netherlands, Australia, Thailand Research Collaboration 
104 Ratchdumri Road Pathumwan, 
Bangkok 10330, Thailand</othercollaboratoraddress>
      <othercollaboratorcountry>Thailand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose is to investigate whether HIV and HIV medication can affect certain areas of brain function. This study will look at possible changes in brain function including memory, concentration and thought processes to see if there are any differences between the two doses of efavirenz used in the Encore1 study and also the level of efavirenz in the blood

http://clinicaltrials.gov/ct2/show/NCT01516060?term=Encore1&amp;rank=4</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Hospital</ethicname>
      <ethicaddress>390 Victoria Street  
Darlinghurst NSW 2010</ethicaddress>
      <ethicapprovaldate>19/12/2011</ethicapprovaldate>
      <hrec>HREC/10/SVH/34</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Rebekah Puls</name>
      <address>Gate 9
High Street
Kennsington
Univeristy of New South Wales
Sydney NSW
2052</address>
      <phone>+61293850900</phone>
      <fax>+6129385 0920</fax>
      <email>encore@kirby.unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anna Donaldson</name>
      <address>Gate 9
High Street
Kennsington
Univeristy of New South Wales
Sydney NSW
2052</address>
      <phone>+61293850900</phone>
      <fax>+6129385 0920</fax>
      <email>adonaldson@kirby.unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anna Donaldson</name>
      <address>Gate 9
High Street
Kennsington
Univeristy of New South Wales
Sydney NSW
2052</address>
      <phone>+61293850900</phone>
      <fax>+6129385 0920</fax>
      <email>adonaldson@kirby.unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>